Energy Sensing
Preclinical studies examine AMPK, a pathway involved in sensing cellular energy availability and coordinating metabolic responses.
Explore mitochondrial and metabolic research with personalized medical guidance.
Book Your AppointmentMOTS-c is a 16-amino-acid peptide derived from mitochondrial DNA. Scientists study its role in cellular energy signaling and responses to metabolic stress.

Emerging research: MOTS-c is investigational and not FDA-approved. Naturally occurring signaling and experimental treatment are different questions; clinical benefits and long-term safety remain uncertain.
Mitochondria produce energy and communicate with the rest of the cell. MOTS-c research explores how those signals relate to changing energy demands.

Preclinical studies examine AMPK, a pathway involved in sensing cellular energy availability and coordinating metabolic responses.
Research explores communication between mitochondria and the nucleus during metabolic stress. These mechanisms do not by themselves establish a clinical treatment.
The science spans laboratory models, animal experiments, and human observations. Each type of evidence answers a different question.
Experimental work examines glucose use and insulin-sensitivity pathways. It does not establish MOTS-c as a treatment for diabetes or a substitute for prescribed care.
Human research has measured naturally occurring MOTS-c around exercise. This does not show that administering it reproduces the benefits of physical activity.
Researchers explore how cells adapt to different fuel sources and energy demands. Clinical improvements in energy or weight cannot be assumed.
Mitochondrial function changes with age, making these signals a research interest. Claims of reversing aging or extending human life are not established.
The MOTS-MET study record describes a Phase 2a, placebo-controlled trial in adults with prediabetes and overweight or obesity.

The record describes assessments of insulin sensitivity and safety. No results were posted when reviewed on September 9, 2026. Registration does not mean FDA approval or confirmation that the intervention works.
Repeated-use safety, interactions, and a validated clinical regimen have not been established.

FDA has highlighted peptide aggregation, impurities, product characterization, and possible immune-reaction concerns.
Injection can cause local reactions or infection. Possible metabolic effects and interactions with glucose-lowering drugs require study rather than assumptions of compatibility.
Discuss medications, pregnancy or breastfeeding, and significant medical conditions with your provider. Limited data cannot establish safety for these groups.
Adding MOTS-c to other peptides or metabolic medications does not establish extra benefit. Combination safety and effective dosing remain uncertain.
Clear information about the product, evidence, and regulatory status belongs in every treatment discussion.
Compounding advisory review is separate from drug approval. A committee discussion or recommendation does not itself establish final list inclusion or availability.
Any prescribing or compounding must satisfy current requirements. Pharmacy licensure and purity testing do not establish permission to compound an ingredient or prove clinical benefit.
Compounded medicines are not FDA-approved. This page does not promise a MOTS-c prescription or a future availability date.
If you are concerned about fatigue, weight, or blood glucose, begin with an evaluation of your symptoms and health history.
Review sleep, activity, nutrition, medications, and relevant medical conditions. Testing should be guided by your individual circumstances.
Our Pasadena team can discuss established care options, follow-up, and research questions without assuming an investigational peptide is the answer.

Practical answers about the research and your care options.

No. MOTS-c remains investigational. Research registration or compounding review does not establish drug approval.
Clinical benefits are not established. Early experimental findings and a registered trial are not a substitute for completed human results.
No evidence establishes MOTS-c administration as a replacement for physical activity. Exercise-related changes in natural peptide levels answer a different scientific question.
A validated clinical regimen is not established. A research protocol is not a self-treatment guide.
MOTS-c is prohibited at all times under WADA rules. Athletes should consult their anti-doping organization before using any medication, peptide, or supplement.
Interactions are not adequately characterized. Review all medications and supplements with your clinician; do not adjust prescribed treatment to add an investigational compound.
The full adverse-effect profile is incomplete. Product impurities, immune reactions, injection-related risks, and unintended metabolic effects are concerns.
A review of your concerns, health history, research questions, and appropriate care options. A consultation does not guarantee access to MOTS-c.
Meet with our medical team to discuss your concerns and build a personalized care plan.
Book Your AppointmentMOTS-c is investigational and not FDA-approved. This page is educational and does not establish treatment availability or replace medical advice. Human benefits and long-term safety remain uncertain.
Clinical, regulatory, and research sources. Laboratory findings and study registration do not establish treatment outcomes.